Angiomammography for Breast Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Breast CancerAngiomammography - DiagnosticTest
Eligibility
18+
Female
What conditions do you have?
Select

Study Summary

This trial is looking at whether a less expensive and more readily available diagnostic modality, namely CESM, is as effective as MRI in predicting the response of a malignant breast tumor to neoadjuvant chemotherapy and the chances of achieving a pCR.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Cycle 2 (each cycle being 21 days), i.e., after the chemotherapy on day 1 of cycle 2 and before cycle 3.

Day 21
Number of patients with a pCR accoreding to angiomammography, based on a 50% reduction in lesion size at angiomammography
Prediction of pCR using angiomammography, based on a 50% reduction in lesion size at angiomammography

Trial Safety

Trial Design

1 Treatment Group

Neoadjuvant chemotherapy
1 of 1

Experimental Treatment

100 Total Participants · 1 Treatment Group

Primary Treatment: Angiomammography · No Placebo Group · N/A

Neoadjuvant chemotherapy
DiagnosticTest
Experimental Group · 1 Intervention: Angiomammography · Intervention Types: DiagnosticTest

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: cycle 2 (each cycle being 21 days), i.e., after the chemotherapy on day 1 of cycle 2 and before cycle 3.

Who is running the clinical trial?

CHU de Quebec-Universite LavalLead Sponsor
152 Previous Clinical Trials
101,367 Total Patients Enrolled
3 Trials studying Breast Cancer
1,031 Patients Enrolled for Breast Cancer

Eligibility Criteria

Age 18+ · Female Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Neoadjuvant chemotherapy with or without concomitant targeted therapy.
You are female aged 18 and over.\n
You have histologically proven breast cancer by large gauge needle.